Patients' experiences of atrial fibrillation and non-vitamin K antagonist oral anticoagulants (NOACs), and their educational needs: A qualitative study

被引:27
|
作者
Clarkesmith, Danielle E. [1 ]
Lip, Gregory Y. H. [1 ,2 ]
Lane, Deirdre A. [1 ,2 ]
机构
[1] Univ Birmingham, Sandwell & West Birmingham Hosp NHS Trust, City Hosp, Inst Cardiovasc Sci, Dudley Rd, Birmingham B18 7QH, W Midlands, England
[2] Aalborg Univ, Dept Clin Med, Aalborg Thrombosis Res Unit, Aalborg, Denmark
关键词
Atrial fibrillation; Non-vitamin K antagonist oral anticoagulants; Patient education; Dabigatran; Warfarin; Anticoagulation; NET CLINICAL BENEFIT; STROKE PREVENTION; DECISION AID; OF-LIFE; ANTITHROMBOTIC THERAPY; MODELING ANALYSIS; DABIGATRAN; ADHERENCE; WARFARIN; POPULATION;
D O I
10.1016/j.thromres.2017.03.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Qualitative research on atrial fibrillation (AF) patient's experiences and perceptions of taking the non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention is limited. This study explores patients' experiences of dabigatran and their recommendations for development of educational materials. Patients and methods: Semi-structured individual interviews with 8 warfarin-naive and 8 warfarin-experienced AF patients, using qualitative deductive thematic analysis. Results: The four main overarching themes included: understanding the diagnosis; reaching a treatment decision; challenges of living with OAC; and patient perceptions of treatment. Patients discussed their shock of diagnosis, and seeking information and support at that time. Narratives suggest patients preferred to be led by the doctor when making treatment decisions, and would often compare dabigatran to warfarin. Patients reported side-effects and challenges with both treatment options, and discussed their beliefs surrounding medications, including misconceptions. In addition to the original framework, two further themes were added: challenges of living with AF, and patient recommendations. Generally patients found AF symptoms distressing, which impacted their quality of life. Patient recommendations included the content and delivery of educational materials and development of tools to help with their understanding of AF and anticoagulation, as well as treatment adherence and anxiety surrounding symptoms and side effects. Conclusion: Patient recommendations emphasised the need for interventions to relieve anxiety surrounding the diagnosis and possible treatment side effects. Tailored 'disease-specific' support is essential to ensure efficacious treatment. This qualitative study highlights the need for patient involvement in the development of educational materials and resources for patients commencing treatment with NOACs. Crown Copyright (C) 2017 Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:19 / 27
页数:9
相关论文
共 50 条
  • [1] Non-Vitamin K Antagonist Oral Anticoagulants in the Treatment of Atrial Fibrillation
    Fanaroff, Alexander C.
    Ohman, E. Magnus
    ANNUAL REVIEW OF MEDICINE, VOL 70, 2019, 70 : 61 - 75
  • [2] Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Thrombocytopenia
    Janion-Sadowska, Agnieszka
    Papuga-Szela, Elbieta
    Lukaszuk, Robert
    Chrapek, Magdalena
    Undas, Anetta
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2018, 72 (03) : 153 - 160
  • [3] How safe are non-vitamin K antagonist oral anticoagulants in atrial fibrillation?
    De Caterina, Raffaele
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2016, 18 (0I) : 1 - 6
  • [4] Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation
    Plitt, Anna
    Ruff, Christian T.
    Giugliano, Robert P.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2016, 30 (05) : 1019 - +
  • [5] Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Atrial Fibrillation
    Cha, Myung-Jin
    Choi, Eue-Keun
    Han, Kyung-Do
    Lee, So-Ryoung
    Lim, Woo-Hyun
    Oh, Seil
    Lip, Gregory Y. H.
    STROKE, 2017, 48 (11) : 3040 - +
  • [6] Cessation of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
    Middeldorp, Melissa E.
    Gupta, Aashray
    Elliott, Adrian
    Kadhim, Kadhim
    Thiyagarajah, Anand
    Gallagher, Celine
    Hendriks, Jeroen
    Linz, Dominik
    Emami, Mehrdad
    Mahajan, Rajiv
    Lau, Dennis
    Sanders, Prashanthan
    HEART, 2021, 107 (12) : 971 - 976
  • [7] The safety and efficacy of non-vitamin K antagonist oral anticoagulants in atrial fibrillation in the elderly
    Patti, Giuseppe
    Cavallari, Ilaria
    Hanon, Olivier
    De Caterina, Raffaele
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 265 : 118 - 124
  • [8] Non-vitamin K antagonist oral anticoagulants in valvular atrial fibrillation
    Basaran, Ozcan
    Dogan, Volkan
    Sahin, Cem
    Biteker, Murat
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 212 : 357 - 357
  • [9] Impact of frailty on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a nationwide cohort study
    Grymonprez, Maxim
    Petrovic, Mirko
    De Backer, Tine L.
    Steurbaut, Stephane
    Lahousse, Lies
    EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES, 2024, 10 (01) : 55 - 65
  • [10] Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients undergoing elective cardioversion
    Itainen, Saga
    Lehto, Mika
    Vasankari, Tuija
    Mustonen, Pirjo
    Kotamaki, Mervi
    Numminen, Anna
    Lahtela, Heli
    Bah, Aissa
    Hartikainen, Juha
    Hekkala, Anna-Mari
    Airaksinen, Juhani K. E.
    EUROPACE, 2018, 20 (04): : 565 - 568